A Second Opinion: Looking at the new results from the Phase 3 CARTITUDE-4 study of CARVYKTI presented at ASH2024, as well as the Phase II iMMagin data on Anito-Cel from Gilead/Arcellx

Executed on:Jan 9, 2025 4:30 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Ohio State UniversityAssistant Professor of Hematology at Ohio State University.
Manages 100 patients with relapsed/refractory multiple myeloma.
Research focuses on the development of novel anti-myeloma drugs through participation in clinical trials; clinical focus is on high risk patients and those with relapsed/refractory disease.

Interview Goal

This interview aims to explore the recent advancements and clinical data presented by Legend Biotech and J&J regarding their CARVYKTI (ciltacabtagene autoleucel; cilta-cel) program for multiple myeloma. We will also discuss the potential of Anito-Cel, currently in development by Gilead/Acellx.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.